These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 7634441)

  • 1. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty.
    Hamon M; Bauters C; Amant C; McFadden EP; Helbecque N; Lablanche JM; Bertrand ME; Amouyel P
    Circulation; 1995 Aug; 92(3):296-9. PubMed ID: 7634441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty.
    Samani NJ; Martin DS; Brack M; Cullen J; Chauhan A; Lodwick D; Harley A; Swales JD; de Bono DP; Gershlick AH
    Lancet; 1995 Apr; 345(8956):1013-6. PubMed ID: 7723497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty.
    van Bockxmeer FM; Mamotte CD; Gibbons FA; Burke V; Taylor RR
    Circulation; 1995 Oct; 92(8):2066-71. PubMed ID: 7554183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors.
    Jørgensen E; Kelbaek H; Helqvist S; Jensen GV; Saunamäki K; Kastrup J; Havndrup O; Bundgaard H; Kyst Madsen J; Christiansen M; Andersen PS; Reiber JH
    J Am Coll Cardiol; 2001 Nov; 38(5):1434-9. PubMed ID: 11691520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty.
    Okamura A; Ohishi M; Rakugi H; Katsuya T; Yanagitani Y; Takiuchi S; Taniyama Y; Moriguchi K; Ito H; Higashino Y; Fujii K; Higaki J; Ogihara T
    Angiology; 1999 Oct; 50(10):811-22. PubMed ID: 10535720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty.
    Völzke H; Hertwig S; Rettig R; Motz W
    Clin Sci (Lond); 2000 Jul; 99(1):19-25. PubMed ID: 10887054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ace D/I polymorphism and incidence of post-PTCA restenosis: a prospective, angiography-based evaluation.
    Zee RY; Fernandez-Ortiz A; Macaya C; Pintor E; Lindpaintner K; Fernandez-Cruz A
    Hypertension; 2001 Mar; 37(3):851-5. PubMed ID: 11244007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement.
    Koch W; Kastrati A; Mehilli J; Böttiger C; von Beckerath N; Schömig A
    Circulation; 2000 Jul; 102(2):197-202. PubMed ID: 10889131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-converting enzyme insertion/deletion polymorphism does not influence the restenosis rate after coronary stent implantation.
    Ferrari M; Mudra H; Grip L; Voudris V; Schächinger V; de Jaegere P; Rieber J; Hausmann D; Rothman M; Koschyk DH; Figulla HR;
    Cardiology; 2002; 97(1):29-36. PubMed ID: 11893827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E polymorphism does not predict risk of restenosis after coronary angioplasty.
    Samani NJ; Martin DS; Brack M; Cullen J; Wallis R; Lodwick D; Chauhan A; Harley A; Thompson JR; Gershlick AH; de Bono DP
    Atherosclerosis; 1996 Sep; 125(2):209-16. PubMed ID: 8842352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between angiotensin converting enzyme gene polymorphism, coronary artery disease, and stent restenosis: the role of angiotensin converting enzyme inhibitors in stent restenosis in patients with diabetes mellitus.
    Guneri S; Baris N; Aytekin D; Akdeniz B; Pekel N; Bozdemir V
    Int Heart J; 2005 Sep; 46(5):889-97. PubMed ID: 16272779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting.
    Amant C; Bauters C; Bodart JC; Lablanche JM; Grollier G; Danchin N; Hamon M; Richard F; Helbecque N; McFadden EP; Amouyel P; Bertrand ME
    Circulation; 1997 Jul; 96(1):56-60. PubMed ID: 9236417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity.
    Jørgensen B; Simonsen S; Endresen K; Forfang K; Egeland T; Thaulow E
    Am Heart J; 2000 Mar; 139(3):482-90. PubMed ID: 10689263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between the insertion/deletion polymorphism of the angiotensin I converting enzyme gene and restenosis after coronary stenting.
    Gürlek A; Güleç S; Karabulut H; Bokesoy I; Tutar E; Pamir G; Alpman A; Toydemir R; Aras O; Oral D
    J Cardiovasc Risk; 2000 Dec; 7(6):403-7. PubMed ID: 11155292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE gene polymorphism and coronary restenosis.
    Bauters C; Amouyel P; Bertrand ME
    Semin Interv Cardiol; 1999 Sep; 4(3):145-9. PubMed ID: 10545620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in restenosis propensity of devices for transluminal coronary intervention. A quantitative angiographic comparison of balloon angioplasty, directional atherectomy, stent implantation and excimer laser angioplasty. CARPORT, MERCATOR, MARCATOR, PARK, and BENESTENT Trial Groups.
    Foley DP; Melkert R; Umans VA; de Jaegere PP; Strikwerda S; de Feyter PJ; Serruys PW
    Eur Heart J; 1995 Oct; 16(10):1331-46. PubMed ID: 8746901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty.
    Foley DP; Melkert R; Serruys PW
    Circulation; 1994 Sep; 90(3):1239-51. PubMed ID: 8087933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.
    Desmet W; Vrolix M; De Scheerder I; Van Lierde J; Willems JL; Piessens J
    Circulation; 1994 Jan; 89(1):385-92. PubMed ID: 8281674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.